ClinicalTrials.Veeva

Menu

Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation

H

Hillel Yaffe Medical Center

Status

Unknown

Conditions

Pacemaker Implantation
Pain

Treatments

Drug: Dormicum 2.5 mg and Pethidine 25 mg
Drug: EMLA Analgesic Cream

Study type

Interventional

Funder types

Other

Identifiers

NCT02016976
0094-13-HYMC

Details and patient eligibility

About

The investigators believe that the local anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) cream will lessen pain and reduce the need for anesthesia and analgesia, when implanting a permanent pacemaker.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients undergoing pacemaker implantation

Exclusion criteria

  • Dementia Patients
  • Psychiatric Patients
  • Unconscious Patients
  • Patients with sensitivity to EMLA

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 2 patient groups

EMLA analgesic cream
Active Comparator group
Description:
Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
Treatment:
Drug: EMLA Analgesic Cream
Routine treatment
Active Comparator group
Description:
Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
Treatment:
Drug: Dormicum 2.5 mg and Pethidine 25 mg

Trial contacts and locations

1

Loading...

Central trial contact

Anat Glass, RN, MA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems